COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Dehydroepiandrosterone Supplementation for Poor Responder Patients During in Vitro Fertilization Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01145144
Recruitment Status : Completed
First Posted : June 16, 2010
Last Update Posted : June 16, 2010
Information provided by:
Meir Medical Center

Brief Summary:
The aim of this study was to evaluate the effect of dehydroepiandrosterone supplementation on in vitro fertilization performance and outcome among poor-responder patient.

Condition or disease Intervention/treatment Phase
Ovarian Stimulation Drug: dehydroepiandrosterone crystalline fine powder Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : January 2008
Actual Primary Completion Date : July 2009
Actual Study Completion Date : July 2009

Resource links provided by the National Library of Medicine

Drug Information available for: Prasterone

Arm Intervention/treatment
Experimental: DHEA supplementation
DHEA was added to induction of ovulation by recombinant FSH and recombinant LH, in IVF long protocol
Drug: dehydroepiandrosterone crystalline fine powder
No Intervention: only induction of ovulation by same long protocol without DHEA

Primary Outcome Measures :
  1. peak estradiol level.
  2. number of retrieved oocytes.
  3. Embryos that were graded as a top quality (according to the number of cells and percent of fragmentation)
  4. number of embryos reserved for transfer.

Secondary Outcome Measures :
  1. pregnancy rate.
  2. live birth rate.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 42 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • previous poor response to ovarian stimulation in IVF.

Exclusion Criteria:

  • patients over the age of 42
  • patients who received DHEA at any time.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01145144

Layout table for location information
Meir Medical center IVF unit
kfar Saba, Israel
Meir Medical Center
Kfar Sava, Israel
Sponsors and Collaborators
Meir Medical Center
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Adriam Shulman, IVF Unit Meir Medical Center Identifier: NCT01145144    
Other Study ID Numbers: mmc07204-2006ctil
First Posted: June 16, 2010    Key Record Dates
Last Update Posted: June 16, 2010
Last Verified: June 2010
Keywords provided by Meir Medical Center:
IVF outcome
long protocol IVF
recombinant LH
embryo quality
pregnancy rate
live birth rate
poor response to ovarian stimulation
Additional relevant MeSH terms:
Layout table for MeSH terms
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs